United States · Investor

NGN Capital

Last cheque observed Sep 2015. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

Email

VC firmQuiet

SeedSeries ASeries BEhealthHealthLongevity

Cheques on record
0%of best year0cheques in 12 months, 21 on record
Since the last cheque4092days00hrs00min00sec
Median round$20MRounds led0 of 21Sole investor1 roundsExits5 from the portfolioMostly inUnited States, 81%
Pitch NGN Capital

NGN Capital highlights

  1. 01

    21 rounds on record

  2. 02

    Mostly Series B and Series C: 62% of its rounds

  3. 03

    Sole investor in 1 rounds, median $6.6M

  4. 04

    5 exits from the portfolio

What they do

The site lists 'Portfolio Companies' and 'Team' but does not explicitly describe its investment activities.From their own website
Type
VC firm (from a list, unverified)
Cheque size
Not stated
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
EhealthHealthLongevity
Based in
New York, United States
Cold pitches
Not accepted

The record

Every round we can evidence, newest first21 appearances

  1. 2015

    1 round

  2. Sept
    Exosome DiagnosticsSeries B · US$18MWith 4 others
  3. 2014

    1 round

  4. Mar
    Exosome DiagnosticsSeries B · US$27MWith 4 others
  5. 2012

    1 round

  6. Nov
    EndosenseSeries C · CH · finsmes.com$40MWith 7 others
  7. 2010

    4 rounds

  8. Dec
    Small Bone InnovationsSeries F · US · finsmes.com$15MWith 2 others
  9. Jul
    Artisan PharmaSeries C · US · masshightech.com$3.0MWith 4 others
  10. May
    Exosome DiagnosticsSeries A · US · exosomedx.com$20MWith 1 other
  11. Mar
    Artisan PharmaSeries B · US · artisanpharma.net$22MWith 3 others
  12. 2009

    4 rounds

  13. Sept
    BeneChillSeries C · US · onbiovc.com$14MWith 2 others
  14. Apr
    Small Bone InnovationsSeries D · US · totalsmallbone.com$108MWith 4 others
  15. Apr
    AerovanceVenture · US · venturebeat.com$38MWith 7 others
  16. Apr
    CerapedicsSeries B · US · devicespace.com$15MWith 1 other
  17. 2008

    2 rounds

  18. May
    ACT BiotechSeries A · US · sec.gov$6.6MSole investor
  19. Jan
    Small Bone InnovationsSeries C · US · totalsmallbone.com$36MWith 4 others
  20. 2007

    3 rounds

  21. Mar
    Nitec Pharma AGSeries B · CH$26MWith 2 others
  22. Mar
    AerovanceSeries C · US · deals.venturebeat.com$60MWith 5 others
  23. Jan
    Tigris PharmaceuticalsSeries B · US$16MWith 2 others
  24. 2006

    2 rounds

  25. Sept
    Artisan PharmaSeries A · US · artisanpharma.net$39MWith 4 others
  26. Mar
    EKOS CorporationSeries C · US · ekoscorp.com$26MWith 8 others
  27. 2005

    2 rounds

  28. Feb
    EKOS CorporationSeries B · US · ekoscorp.com$18MWith 3 others
  29. Feb
    JeriniVenture · DE$20MWith 4 others
  30. 2004

    1 round

  31. Dec
    Santhera Pharmaceuticals HoldingSeries A · CH$19MWith 1 other

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration3 named

JRJohn Richard CostantinoManageriForm ADV
KSKenneth Samuel AbramowitzManageriForm ADV
PJPeter JohannManageriForm ADV

We also hold 8 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$113Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
Legal name
NGN Capital LLC
SEC number
CRD 162938

Exits from the portfolio

Companies it backed that were later bought or listed5 in all

Small Bone InnovationsBought by Stryker Corporation$375MJun 2014
EndosenseBought by St. Jude Medical$170MAug 2013
EKOS CorporationBought by BTG$220MMay 2013
Artisan PharmaBought by Asahi Kasei PharmaUndisclosedNov 2011
JeriniBought by Shire$554MJul 2008

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as NGN Capital. A count of rooms they were both in, not a relationship either has claimed.

3i GroupPrivate equity3rounds togetherBio*One CapitalCorporate VC3rounds togetherForbion Capital PartnersPrivate equity3rounds togetherJafco VenturesGrowth equity3rounds togetherMedVenture AssociatesVC firm3rounds togetherAlta PartnersVC firm2rounds togetherApax PartnersPrivate equity2rounds togetherArcus VenturesVC firm2rounds togetherBurrill & CompanyVC firm2rounds togetherClarus VenturesVC firm2rounds togetherEGS Healthcare Capital PartnersVC firm2rounds togetherLehman BrothersHedge fund2rounds together

Quick answers about NGN Capital

What does NGN Capital invest in?

NGN Capital invests most often at Series B and Series C (62% of the rounds on record), in sectors such as Ehealth, Health and Longevity.

How active is NGN Capital?

21 investments on record, 0 of them in the last 12 months. The most recent was in Sept 2015.

How big are NGN Capital's cheques?

The median round it joins is $20M.

Does NGN Capital lead rounds?

Rarely, if at all: none of its 21 investments on record names it as the lead.

Where does NGN Capital invest?

Most of the companies it backs are in the United States (81%) and Switzerland (14%).

Is NGN Capital investing now?

No investments in the last 12 months; the latest was in Sept 2015.

Who does NGN Capital invest alongside?

Most often 3i Group (3 rounds together), Bio*One Capital (3 rounds together) and Forbion Capital Partners (3 rounds together).

What kind of investor is NGN Capital?

NGN Capital is a VC firm based in New York, United States.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it